AGORACOM-JC « AGORACOM Small-cap Investor Relations Blog

Author Archive

Loop $MTRX.ca Signs Contract with bdG Sports LLC. to Deliver Contact Tracing and Automated Marketing Solutions for NBA, NHL, NCAA and PGA Sporting Events $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 7:09 AM on Thursday, August 13th, 2020

Announced the signing of a channel reseller partnership with Kentucky-based bdG Sports LLC (“bdG”) a leading representation, event management and public relations firm operating within the global sports marketing industry.
bdG Sports is one of the largest providers of college basketball content in the United States, managing multiple NCAA Division I tournaments across North America, including destination tournaments in Southwest Florida, Las Vegas, Canada, and The Bahamas
The firm manages two professional golf tournaments on the Korn Ferry Tour in the Caribbean, and has an extensive background with both the LPGA and PGA TOUR
The firm also boasts relationships with such brands as Nike, ESPN, Gatorade, and MGM Resorts International, among others.

VANCOUVER, BC, Aug. 13, 2020 – Loop Insights Inc. (MTRX:TSXV) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive automated marketing, contact tracing, and contactless solutions to the brick and mortar space, announces the signing of a channel reseller partnership with Kentucky-based bdG Sports LLC (“bdG”) a leading representation, event management and public relations firm operating within the global sports marketing industry.

LOOP CONTACT TRACING SOLUTION PROVIDES BDG SPORTING EVENTS WITH AN OPPORTUNITY TO COMMENCE AND PROVIDE ECONOMIC RECOVERY FOR CLIENTS

bdG Sports is one of the largest providers of college basketball content in the United States, managing multiple NCAA Division I tournaments across North America, including destination tournaments in Southwest Florida, Las Vegas, Canada, and The Bahamas. The firm manages two professional golf tournaments on the Korn Ferry Tour in the Caribbean, and has an extensive background with both the LPGA and PGA TOUR. The firm boasts relationships with such brands as Nike, ESPN, Gatorade, and MGM Resorts International, among others. As a result of COVID-19, these staple events and many other bdG events have been disrupted, with no plans for commencement without a solution for the safety of fans, athletes, and staff.

President and CEO of bdG Sports, Brooks Downing, said: “Many within our extensive network of business are desperately searching for innovative solutions that will allow them the opportunity to support a safe environment for fans, staff and athletes, but also optimize their revenue streams that warrant the restart of operations. Loop effectively solves both of these problems with its leading contact-tracing solution which will provide the confidence needed as teams make decisions to restart their schedules. And while this tool will allow fans to return to events, Loop’s contactless, artificial intelligence marketing solutions will provide personalized promotions and targeted engagement, leading to higher conversions and transaction revenue at all events. This level of personalized omni-channel marketing is incredibly valuable for our clients’ resumption plans.”

BDG PROVIDES DIRECT ACCESS TO ITS LIVE GLOBAL SPORTING EVENTS AND TO ITS LARGE NETWORK OF CLIENTS WITHIN NBA, NHL, NCAA AND PGA

In addition to implementing Loop’s contact tracing product into its current and future events, bdG Sports also plays host to major global sports events and will be implementing Loop’s solutions to reinvent the live fan engagement experience, consisting of real-time personalized fan engagement.

Additionally, bdG will represent Loop as a reseller to its current and future clients and enables direct access to the bdG Sports client base, which the Company anticipates will accelerate its growth opportunities in the sports industry.

Loop CEO, Rob Anson, stated: “This is a major opportunity for Loop as live event operators are looking for two things that we can immediately solve. First, they are desperately looking to safely re-open facilities in efforts to save their respective seasons, and secondly, they are looking for new line revenue opportunities to offset the losses from reduced fan capacity in stadium. This partnership with globally renowned bdG Sports is major third-party validation of our abilities to deliver these solutions. We look forward to leading the way with them toward the safe and profitable resumption of major sporting events.”

Watch Loop CEO, Rob Anson and bdG Sports CEO, Brooks Downing discuss their new partnership https://youtu.be/cL5wfYNO-Qs

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&A https://agoracom.com/ir/LoopInsights/forums/discussion

About bdG Sports:
bdG Sports is a representation, event management, and public relations firm operating on an international platform within the sports marketing industry. bdG manages multiple college basketball and college hockey events in the United States each season with events in Southwest Florida, Las Vegas and The Bahamas. bdG’s golf division manages the season-opening tournaments of the Korn Ferry Tour each January in The Bahamas, hosts premium Pro-Ams throughout the year and launched the Unbridled Tour mini-tour series in 2020. For more information, visit www.bdglobalsports.com or follow on @bdGlobalSports on Twitter, Facebook or Instagram.

About Loop Insights:
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.

Forward-Looking Statements/Information:

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE LOOP Insights Inc.

Tags: AI, covid19, Covid19 tracing, CSE, internet of things, IOT
Posted in All Recent Posts, Featured, Loop Insights Inc. | Comments Off on Loop $MTRX.ca Signs Contract with bdG Sports LLC. to Deliver Contact Tracing and Automated Marketing Solutions for NBA, NHL, NCAA and PGA Sporting Events $QUIS.ca $MCLD.ca $NXO.ca

ImagineAR $IP.ca $IPNFF and The Pittsburgh Gateways Corporation Sign MOU To Integrate Augmented Reality Into the Energy Innovation Center $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:04 AM on Thursday, August 13th, 2020

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Announced the signing of an MOU with the Pittsburgh Gateways Corporation, a developer of technology-based research centers in the United States
Since its inception, Gateways has established, or formed collaborative alliances with, over 30 technology centers, primarily in Western Pennsylvania, but extending throughout the Northeastern and Midwestern United States
The organization has also assisted in the formation of over 60 new or development-stage ventures, many of which are thriving today as successful business and economic development enterprises. Its efforts have contributed to the creation of thousands of jobs.

VANCOUVER, BC and ERIE Pa., Aug. 13, 2020 ImagineAR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses, retailers and organizations to instantly create their own AR mobile campaigns, is pleased to announce the signing of an MOU with the Pittsburgh Gateways Corporation (“Gateways”), a developer of technology-based research centers in the United States.

Since its inception, Gateways has established, or formed collaborative alliances with, over 30 technology centers, primarily in Western Pennsylvania, but extending throughout the Northeastern and Midwestern United States. The organization has also assisted in the formation of over 60 new or development-stage ventures, many of which are thriving today as successful business and economic development enterprises. Its efforts have contributed to the creation of thousands of jobs.

Pittsburgh Gateways Corporation CEO Robert Meeder stated: “As an economic development organization, we focus on integrating advanced immersive technology such as augmented reality into our center as well as introducing it to our tenants. ImagineAR is a leader in the mobile augmented reality in the North America and we are truly excited to partner with them and drive new AR engagements and revenue together. The applications of ImagineAR into our Energy Innovation Center will be extensive.”

Gus Frerotte, 15 year NFL Pro Bowl QB and Developer/Coordinator of Media and Communications Operations at the EIC, added “From the first moment I set foot in the EIC I knew I wanted to be part of this team. I admire the leadership of Pittsburgh Gateways Corporation and their mission for the EIC. The EIC is a robust intersection of research, training and community service and my goal is to help with the application of my skills and experience in communications and the development of human performance tools. When I first spoke with Neal Bendesky, VP Sports & Events of ImagineAR Inc., I knew that the EIC would benefit from this collaboration. I am excited for the future as the EIC and its partners come to life.”

ImagineAR CEO Paul Silverrstieen added: “We are honored to be selected as the Augmented Reality Platform Solution for the prestigious Gateways organization. Their reputation as a leader in the energy sector as well as high-tech incubators, provides ImagineAR the opportunity to work with energy and entrepreneurial companies to create AR engagements and activations together. This partnership is expected to develop a new sector revenue channel for ImagineAR. “

About Pittsburgh Gateways Corporation

Pittsburgh Gateways Corporation’s mission is to provide strategic planning, development and direct management assistance for communities, community-based economic development organizations, research & academic institutions, and private entities seeking the acceleration of technology-based businesses. Incorporated into this mission is our goal to combat community deterioration in the City of Pittsburgh and other economically distressed areas of Pennsylvania. Pittsburgh Gateways Corporation is registered as a 501(c)(3) non-profit organization. The website is https://www.pghgateways.org/.

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, (products, landmarks and more to instantly engage videos, information, advertisements, coupons,3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies. The AR Platform is available as an SDK Plug-in for existing mobile apps.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

For more information or to explore working with Imagination Park, please email [email protected], or visit www.imagineAR.com.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagination Park Entertainment Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although Imagine AR Inc. believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR Inc. can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR Inc. disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE ImagineAR

Tags: AR, augmented reality, Chelsea APPS Factory, CSE, small cap, stocks, tsx
Posted in Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF and The Pittsburgh Gateways Corporation Sign MOU To Integrate Augmented Reality Into the Energy Innovation Center $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Mota Ventures $MOTA.ca to Change Name to Thoughtful Brands Inc. (CSE: TBI) $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM-JC at 7:23 PM on Wednesday, August 12th, 2020

Announced that it will change its name from “Mota Ventures Corp.” to “Thoughtful Brands Inc.” and its ticker symbol from “MOTA” to “TBI”
Subject to the approval of the Canadian Securities Exchange, the Company expects the name change to take effect on August 14, 2020

VANCOUVER, BC / August 12, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce that it will change its name from “Mota Ventures Corp.” to “Thoughtful Brands Inc.” and its ticker symbol from “MOTA” to “TBI”. Subject to the approval of the Canadian Securities Exchange (the “CSE“), the Company expects the name change to take effect on August 14, 2020 when its common shares will begin trading on the CSE under the new name and new ticker symbol.

The Company’s fundamental business continues to be the development and sale of natural health products through its eCommerce technology, with a focus on the CBD and psychedelic medicine sectors. The Company believes that the name and symbol change better reflect the success of its strategic growth and its drive to acquire and develop branded products and research initiatives in the natural health products space.

“The rebranding and new name represent our multi-faceted expansion and evolution strategies moving forward,” said CEO Ryan Dean Hoggan. “The change also reflects our commitment to becoming a global leader in the natural products industry. We are already making pivotal progress in the space through our work in psychedelics research, as well as by making quality hemp-derived CBD products more accessible worldwide through our eCommerce technology platform-and yet we are just starting to scratch the surface.”

The Company’s rebranding is the latest of several recent developments, including its:

European expansion through a joint venture with Franchise Cannabis Corp. whereby the Company will sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its well-established eCommerce platform. (July 2020)
Acquisition of Verrian, a German natural psychedelic development company with the goal of formulating treatments for addictions, including opioids and alcohol. The move propels the Company into the emerging psychedelic market and supports the Company’s forays into the natural health sector beyond the CBD market. (June 2020)

No action is required by existing shareholders with respect to the name and ticker symbol change. Certificates representing common shares of Mota Ventures Corp. will not need to be exchanged as a result of the name change. The name change was approved by the board of directors on August 10, 2020.

About Mota Ventures

Mota Ventures is an established eCommerce technology company that researches, develops, markets and sells natural health products in North America and Europe. The Company has a strong focus on the CBD market, as well as the burgeoning psychedelic medicine sector. Through its direct-to-consumer digital platform, the Company offers multiple well-established hemp-CBD brands, including Nature’s Exclusive, Sativida and Franchise. The Company also owns and operates a 110,000 square foot manufacturing facility in Radebeul, Germany, where its highly skilled team is currently conducting clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction. The Company anticipates future opportunities to create proprietary psilocybin products as legislation related to psychedelics evolves. The Company continues to pursue the acquisition of additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its powerful eCommerce technology platform.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to its plans to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Tags: #Europe, #Psilocybin, #psychedelic, #Sales, Cannabis, CBD, CSE, EBITDA
Posted in Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca to Change Name to Thoughtful Brands Inc. (CSE: TBI) $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

MedX Health $MDX.ca continues its global expansion in the fight against skin cancer $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 5:53 PM on Wednesday, August 12th, 2020

Matthew Bohlsen |

Skin cancer is the most common cancer in the United States and worldwide, but early screening can save lives. Did you know these gruesome facts?

One in every three cancers diagnosed is skin cancer.
Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year.
1 in 5 Americans will develop skin cancer by the age of 70.
More than 2 people die of skin cancer in the U.S. every hour.

Clearly the world needs a much better early skin cancer screening technology.

MedX Health Corp. (TSXV: MDX) is a leading medical device and software company focused on the early detection of skin cancer. MedX has approvals in 35 countries and distribution agreements in place for its key skin cancer diagnostic products – SIAscope and DermSecure™ telemedicine platform.

Following on from MedX’s regulatory approval and distribution agreement in Brazil (read here), the Company recently announced an exciting exclusive distribution agreement to launch SIAscopy on DermSecure™ in Mexico with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico. MedX Mexico plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. MedX Mexico will cover all the upfront costs for application for regulatory approval in Mexico, all marketing costs, and will utilize their large-scale distribution network in Mexico.

MedX Mexico’s, President and CEO, Carlos Vizcaino, states:

“There is a significant opportunity for MedX’s rapid skin assessment technology in Mexico, as skin cancer is a very common type of cancer in Mexico……MedX’s SIAscopy on DermSecure™ Telemedicine platform and advanced SIAscopy imaging technology is a perfect solution to assist dermatologists and physicians in the diagnosis process for early detection of melanoma.”

Masterplan

MedX Health’s masterplan is to continue to rollout distribution agreements with partners globally. So far Brazil and now Mexico are underway. MedX’s revolutionary skin cancer detection device is approved in the USA, Canada, Brazil, Australia, New Zealand, the European Union, Turkey, and many other places. In total MedX’s device has achieved regulatory approval in 35 countries. This means we can expect further distribution agreements in the future to many of the above countries. The potential for future revenues is enormous.

MedX’s business model is similar to Software as a Service (SaaS) companies. The revenue model uses front-end hardware sales coupled with recurring “platform” revenue based on a minimum number of screens per device (360/year at $10/image).

2019 revenues were only small at C$860,248, and 1st quarter 2020 C$95,544, as the Company was impacted by COVID-19 and had yet to ramp up distribution as is now occurring in 2020. For a guide on where revenues are headed the next two years the Beacon Securities report is most useful.

The report’s analysts says MedX has strong visibility on initial orders from the MedX Brazilian distribution partner, that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21. Given that MedX currently trades on a market cap of C$24 million, the C$14 million, if achieved, would mean MedX would trade on a 2022 market cap/sales ratio of only 1.7. Beacon Securities rates MedX Health a ‘buy’ with a Price Target of C$0.45. Given the stock currently trades at C$0.135, the C$0.45 price target represents a very significant upside of 233% or a 3.3 fold gain.

Closing remarks

It is very clear to me that the market is yet to wake up to the potential very large boost in revenues that MedX is working to achieve, now with distribution agreements in both Brazil and Mexico.

Detecting skin cancer is an enormous global need and MedX is working hard to fill this need. MedX has the right device and approvals in 35 countries. All that is needed now is further distribution agreements and revenue to flow. The opportunity for investors to get in early on such a great company with a very bright future still exists. I would not recommend waiting too long as the cheap valuation is unlikely to last long, especially as further new deals are announced.

Source: https://investorintel.com/sectors/biotech-healthcare/biotech-intel/medx-health-continues-global-expansion-fight-skin-cancer/

Tags: CSE, DermSecure, MedX, MoleMate, Simsys, Skin Cancer, stocks, tsx, tsx-v
Posted in All Recent Posts, MedX Health Corporation | Comments Off on MedX Health $MDX.ca continues its global expansion in the fight against skin cancer $DMTK $ICAD $PLSE $SRTS

Binovi Technologies Corp Provides Highlights of Its Investor Conference Call Held on August 11, 2020 $EYPT $KALA

Posted by AGORACOM-JC at 5:42 PM on Wednesday, August 12th, 2020

http://www.smallcapepicenter.com/binovi%20square.png

The call, led by Chairman Terry Booth, CEO Adam Cegielski and Scientific Advisor Dr. Sandra Stoddard PhD, formally announced the Company’s expansion in to the K-12 education sector, drawing attention to the great impact that professional-lead neuro-vision therapy and training can have on learning and reducing the global education gap
By targeting K-12, the company is aiming to get Binovi into over 15,000 schools in Canada and over 130,000 schools in the United States

Toronto, New York – August 12, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN) | (OTC:BNVIF), a leader in neuro-vision performance technology, today shared the key highlights from its Investor Conference call held Tuesday August 11^th, 2020. The call, led by Chairman Terry Booth, CEO Adam Cegielski and Scientific Advisor Dr. Sandra Stoddard PhD, formally announced the Company’s expansion in to the K-12 education sector, drawing attention to the great impact that professional-lead neuro-vision therapy and training can have on learning and reducing the global education gap.

“The plan in place for the next year truly exemplifies the shift necessary to grow the Binovi Platform to a Global and Noble product. Our team has worked tirelessly to develop and drive the commercial success of the platform, and the expansion into k-12 education is a natural evolution of the company’s capabilities to enhance cognitive performance through vision training. The efforts reflect our long-term business strategy and goals,” commented Terry Booth, Binovi Chairman.

Key Highlights from Binovi Investor Call:

Market Potential

Terry: “By targeting K-12, we’re aiming to get Binovi into over 15,000 schools in Canada and over 130,000 schools in the United States.”

Sandra: “I think [the rate of adoption] will skyrocket once we have the data in place about using Binovi. There’s so much research that proves already that vision therapy does improve developmental domains, the reading skills of kids, but we want to be able to show unequivocally that Binovi Touch works.”

Adam: “There are a lot of good tools out there, and there are a lot of companies that have built tools and they’re selling their tools and they’ve done a good job on how they’ve built those tools and how they market those tools; they’ve been very focused and they’ve had market penetration success; We are a platform, a platform that can continuously add technology and expand. We’ve taken a more global approach in our product development.”

Education Impact

Sandra: “Reading at grade level by grade 3 is the highest predictor for high school completion. We know that when kids complete high school it leads to so many more positive outcomes for them. In our field, we know that when kids don’t graduate, it’s close to 90% of kids that aren’t graduating weren’t able to read by grade 3.”

Sandra: “Close to 80% of children that do have learning disabilities in the area of reading meet the criteria for accommodation convergence problems, which literature has shown to lead to issues with accuracy, comprehension, or fluency. We also know that the earlier that we can intervene with individuals, the earlier we can remediate the problem.”

Sandra: “I am incredibly excited about utilizing this platform to really confirm that, if we can intervene early and help kids utilize vision therapy and remediate the vision difficulties, I’d like to be able to prove that it does have an impact on reading performance. If we can demonstrate that intervening early with these individuals can not only improve their ready ability but also improve their ability to attend; lots of kids that have been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) also have vision deficits, so the potential for to globally impact these young kids, not only from a reading perspective but from those attentional learning skills needed to be successful in life, this could be a game-changer for the education field.”

Global Impact

Adam: “Over a billion people suffer from binocular issues.”

Terry: “This is way bigger than cannabis; this is a huge opportunity for investors but also schools, kids, and athletes. This is something that affects millions of people.”

Economic impact

Sandra: “Increasing the number of high school graduates in Canada by just 1% can save $7.7B; we see that not completing high school leads to higher rates of incarceration, lower levels of employment, more health issues.”

Ease of Use

Terry: “Vision training can take as little as 15 minutes per day, supported at home.”

Adam: “The infrastructure exists with support staff in schools and the goal is to use technology to link in with someone at the schools to be a centralized person within the school to work with teachers and simplifying the implementation.”

Sandra: “Having been through a walkthrough of the Binovi Platform for vision therapy, I can say that it is very very easy to use. We’d probably have to make some changes to make it motivational to some of the younger kids, but it is easy to use, all platforms can be integrated into the Binovi Platform, so my data collection can be tracked using Binovi. iPads are familiar, so I can easily see it being adopted into the education system.”

Telehealth

Adam: “Telehealth is a significant reality in the North American marketplace today; it’s really a by-product of the advancement of technology and where we are today. We’ve traditionally been dealing with technology solutions that are impacting us in different ways. I think it’s a unique opportunity now to converge all this technology into one spot. The education environment has never seen such dramatic changes in such a short period of time.”

Adam: “Our CTO, Dr. Mithani, has been working extensively on understanding the necessary pieces that Binovi has to have in place, and to be honest we’ve been on top of this substantially even before COVID hit. We’ve been working towards these things.”

Terry: “In our early discussions, Adam already had the plans in place to make sure that this was available through a telehealth platform. We needed to make this available to people from their homes, and it’s become a far bigger piece of the puzzle.”

“Binovi has the opportunity to be the global leader in how we shape the vision and brains of future generations. Looking ahead, we have implemented a number of initiatives to ensure the Company’s continued growth, and to generate the best possible performance results during these unique times. We are fortunate to support dedicated product users, while relying upon the experience and knowledge of our team to lead us to the next summit,” added Adam Cegielski, Binovi CEO

The expansion into education is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals.

Recent 2020 News Releases:

Binovi Transforming K-12 Global Education Through Guided Classroom Technology Resources

Terry Booth Schedules Investor Conference Call to Discuss Binovi’s New Direction

White House Fellow (1990-91), Eric Phillips, Joins Binovi Technologies as Strategic Advisor

Binovi Technologies Secures VIMA Rev Strobe Lenses Through a Strategic Product Acquisition and Announces Private Placement

Late Filing of Annual Financial Statements:

The company also announces today that it anticipates additional delays in filing its financial statements for the year ended February 29, 2020 and the related management’s discussion and analysis (“MD&A”) and certifications (the “Annual Filings”). The Company has filed an application with the relevant securities authorities requesting that they issue a management cease trade order (an “MCTO”).

As previously announced, the Company had relied upon the blanket relief provided by the Canadian Securities Administrators (the “CSA”) in response to the COVID-19 pandemic to extend the filing deadline for the Annual Filings. Due to ongoing complications in collection of certain required data and documentation to complete the audit of the Company caused by COVID-19, the resulting restrictions in travel and limited access to facilities, the Company does not expect to be able to file the Annual Filings by their respective extended deadlines. The Company will work with its auditors to complete the audit of the Company’s consolidated financial statements, and expects to file the Annual Filings by August 31, 2020.

Pursuant to National Policy 12-203 Management Cease Trade Orders (“NP 12-203”), the Company is requesting that an MCTO be issued. If granted, the MCTO will restrict all trading by the Company’s Chief Executive Officer and Chief Financial Officer, and such other directors, officers and persons as determined by the applicable regulatory authorities, in the Company’s securities. There is no certainty that such order will be granted.

An MCTO will not affect the ability of persons other than the directors, officers and insiders to trade in the Company’s securities. An MCTO will remain in effect until the Annual Filings are filed or until it is revoked or varied. If an MCTO is not granted, the applicable regulatory authorities may issue a cease trade order against the Company for failure to file the Annual Filings within the prescribed time period.

Until the Company completes the Annual Filings, the Company will comply with the alternative information guidelines set out in National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for issuers who have failed to comply with a specified continuous disclosure requirement within the times prescribed by applicable securities laws. The guidelines, among other things, require the Company to issue bi-weekly default status reports by way of a news release so long as the Annual Filings have not been filed.

For additional information on the Company, please visit https://www.binovi.com/investor-reports/

About Binovi Technologies Corp.

Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.

Terry Booth

Chairman

Adam Cegielski

Founder | CEO

Dr. Sandra Stoddard PhD

Scientific Advisor

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://binovi.com/investors/

Forward looking information:

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags: Binovi Touch, CSE, Eli Wilson. Eye therapy, eye training, tsx, tsx-v
Posted in Binovi Technologies Corp. | Comments Off on Binovi Technologies Corp Provides Highlights of Its Investor Conference Call Held on August 11, 2020 $EYPT $KALA

CLIENT FEATURE: Loop Insights $MTRX.ca Leveling the playing field between online retail giants and brick & mortar businesses $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 5:25 PM on Wednesday, August 12th, 2020

(TSXV: MTRX)

WHY LOOP INSIGHTS?

What if you could receive the same personalization and experience you get from online shopping, but in brick and mortar stores? Loop Insights is doing just that.

Brick and mortar retail isn’t going anywhere, but it does need to adapt to offer better in-store customer experiences. Loop Insights solves a significant problem for traditional retailers – big and small – who are losing customers to e-commerce retail.

All e-commerce sites have easy access to company-wide connectivity, real-time insights, and personalized marketing. What Loop is doing is creating those same tools for physical retail, whether it is a restaurant, hotel, casino, store, or stadium.

Loop’s proprietary internet of things (IoT) device, Fobi, makes it all happen. It can be installed in minutes using an API or hardware solution, making Loop’s services ultimately scalable no matter what infrastructure is currently set up in the store.

NORTH AMERICA’S BIGGEST MOBILE COMPANIES BELIEVE

SEEING IS BELIEVING

Now that you have an understanding of the magnitude of the problem and the disruptive power of LOOP, you need to see it for yourself. Watch this short but powerful videos demonstrating how LOOP is being applied across different verticals to solve brick and mortar retail problems.

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Loop Insights is an advertising client of AGORA Internet Relations Corp.

Tags: AI, covid19, Covid19 tracing, CSE, internet of things, IOT, tsx
Posted in AGORACOM Client Feature, All Recent Posts, Featured, Loop Insights Inc. | Comments Off on CLIENT FEATURE: Loop Insights $MTRX.ca Leveling the playing field between online retail giants and brick & mortar businesses $QUIS.ca $MCLD.ca $NXO.ca

HPQ Silicon $HPQ.ca Well-Funded to Accelerate Leading Nano Silicon Initiatives for Batteries and Other Renewable Energy Applications for 2020 and Beyond $PYR.ca $DUK $XEL $NEE

Posted by AGORACOM-JC at 10:05 AM on Wednesday, August 12th, 2020

Announced that since the start of June 2020, the Company has raised over $1,452,401 through the exercise of various financial instruments.
During the period ended June 30, 2020, $182,277 was raised, at an average price of $0.122 per share, through the exercise of 1,087,000 warrants, 178,000 broker warrants and 175,000 broker units.
Furthermore, since the start of Q3 another $1,270,124 was raised, at an average price of $0.121 per share, through the exercise of 7,959,588 warrants, 81,430 brokers warrant and 2,400,000 options.
During the same period the 11,881,738 financial instruments were exercise, HPQ traded 156,507,300 shares for a value of $55,789,137 at an average price of $0.356.
While the volume generated represented 60% of HPQ outstanding shares, the shares issued on exercise represented only 7.6% of the trading volume.

MONTREAL, Aug. 12, 2020 — HPQ Silicon Resources Inc. (“HPQ” or the “Company”) TSX-V: HPQ; FWB: UGE; Other OTC : URAGF; is pleased to announced that since the start of June 2020, the Company has raised over $1,452,401 through the exercise of various financial instruments.

During the period ended June 30, 2020, $182,277 was raised, at an average price of $0.122 per share, through the exercise of 1,087,000 warrants, 178,000 broker warrants and 175,000 broker units. Furthermore, since the start of Q3 another $1,270,124 was raised, at an average price of $0.121 per share, through the exercise of 7,959,588 warrants, 81,430 brokers warrant and 2,400,000 options.

During the same period the 11,881,738 financial instruments were exercise, HPQ traded 156,507,300 shares for a value of $55,789,137 at an average price of $0.356. While the volume generated represented 60% of HPQ outstanding shares, the shares issued on exercise represented only 7.6% of the trading volume.

Presently HPQ cash on hand, liquid investment in public companies, and cash reserved for the PUREVAPTM QRR pilot plant project, total $4,725,221. In addition, the $11,482,557 cash value of outstanding in the money warrants and options, (80% of those are owned by PyroGenesis, Investisement Québec (IQ), insiders and strategic investors), provides HPQ access to over $16M. This is enough sources of funds to develop, to commercial scale, the game changing PUREVAP™ family of processes HPQ is developing with Pyrogenesis namely:

The PUREVAP™ “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential; and
The PUREVAP™ Nano Silicon Reactor (NSiR), a new proprietary process that use PUREVAPTM QRR silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires.”

“Since the start of the year, HPQ has made great strides toward its goal of becoming a leader in the field of Nano silicon materials production, and we very grateful for the market support we have received over the last few months and the resultant financings.” said Bernard Tourillon, President & CEO of HPQ Silicon. “Our PUREVAPTM processes open up unique multibillion-dollar business opportunity for HPQ and PyroGenesis, as we strive to deliver the critical and economically viable Silicon nano- materials required by the surging Li-ion battery market and other large renewable energy markets.”

POTENTIAL OF OUR PUREVAPTM NANO SILICON (Si) REACTOR GETTING NOTICED

The PUREVAPTM NSiR process is purposely being developed to address the fact that current manufacturing processes to make Nano Silicon (Si) Powders are not very scalable and simply too expensive to be commercially feasible, requiring up to US$ 30,000/kg1 selling prices to justify production. HPQ and partner Pyrogenesis are working to develop commercially scalable Nano Silicon powder production and have caught the attention of significant industry players. The company continues to evaluate and discuss potential opportunities under Confidentiality Agreements and cannot provide further commentary at this time.

About Silicon

Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) presently under way. Silicon does not exist in its pure state; it must be extracted from quartz (SiO2), in what has historically been a capital and energy intensive process.

About HPQ Silicon

HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high value specialty silicon products needed for the coming RER.

Working with PyroGenesis Canada Inc. (TSX-V: PYR), a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:

The PUREVAPTM “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential;
- HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
The PUREVAPTM Nano Silicon Reactor (NSiR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires;
- HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries;
- During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAPTM SiNR.

HPQ is also working with industry leader Apollon Solar of France to:

Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders;
- The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries.
- The plan is to deliver porous Si wafer to a battery manufacturer (under NDA) for testing in 2020.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Disclaimers:

The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

For further information contact

Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected]

Posted in Featured, HPQ-Silicon Resources Inc. | Comments Off on HPQ Silicon $HPQ.ca Well-Funded to Accelerate Leading Nano Silicon Initiatives for Batteries and Other Renewable Energy Applications for 2020 and Beyond $PYR.ca $DUK $XEL $NEE

Datametrex $DM.ca Secures COVID-19 Antigen Detection Kits

Posted by AGORACOM-JC at 9:10 AM on Wednesday, August 12th, 2020

Announced that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits
These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes
Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection

TORONTO, Aug. 12, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits. These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes.

The Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection. It is an in-vitro diagnostic medicaldevice to detect the SARS-CoV-2 antigen from a person’s oropharyngeal and nasopharyngeal secretions if the specimen contains antigens to SARS-CoV-2, a colored line appears in the T line area.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy,” said Marshall Gunter, CEO of Datametrex. “These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

PCL states that the clinical sensitivity (confirmed the actual positive of the approved person) is 100% and the clinical specificity (confirmed the actual negative of the negative person) is 97.78%. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

The following certifications have been awarded to these PCL Antigen Test Kits: CE Certificate, Korea FDA, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East- Qatar and UAE, India, Russia, 3 countries in Latin America- Guatemala, Ecuador, and Colombia.

The PCL Antigen Detection kit has the CE Certificate meaning that the manufacturer and products have met EU declaration of standards for health, safety, and environmental protection, allowing this product to be sold within the 22 countries in the European Economic Area.

Worldwide, currently there have been over 19.7M people who have been tested positive for COVID-19 but the actual case count is believed to be higher, as a significant number of asymptomatic people may not have been tested. Even more worrying is that most families have had to wait more than 72 hours for their test results to come back from both public and private labs increasing the possibility of spreading the virus.

Rapid Diagnosis Kit is easy when there are no symptoms even after COVID-19 infection, or when ‘positive’ and ‘negative’ are not evident in tests such as RT-PCR. When an infection occurs, an antigen against COVID-19 is formed in the body after some time, so it is a post-test that is essential as a preventive measure.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Health Canada must approve these COVID-19 test kits before they can be used in Canada. The Company plans to sell these kits in all countries where the kits have been approved for sale.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

About Datametrex

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Forward-Looking Statements

Tags: AI, Antigen Rapid Diagnosis, bot, covid19, CSE, datametrex, investments, PCL, small cap
Posted in All Recent Posts, Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Secures COVID-19 Antigen Detection Kits

Avicanna’s $AVCN.ca RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical #Cannabis by #Shoppers Inc.™ $TRUL.ca $ACB

Posted by AGORACOM-JC at 8:08 AM on Wednesday, August 12th, 2020

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners on the Medical Cannabis by Shoppers™ platform.

This product line includes advanced formulations under the “Cannabis 2.0” regulations that have undergone years of research and development and been manufactured under GMP standards at MediPharm Labs Inc.

The RHO Phyto products are also now available to clinicians and patients at the University Health Network through the Medical Cannabis Real World Evidence study in partnership with Medical Cannabis by Shoppers.

TORONTO, Aug. 12, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its advanced RHO Phyto™ Micro Drop oils are now officially available nationwide in Canada on the Medical Cannabis by Shoppers™ (“Shoppers“) platform as well as through the Medical Cannabis Real-World Evidence study (“MC-RWE study“) at the University Health Network (“UHN“) as announced by the Company on July 15, 2020.

Following years of research and development in collaboration with world class academic and clinical organizations, Avicanna is proud to be launching RHO Phyto, a full formulary of advanced medical cannabis products, for patients and the medical community in Canada. Following the Micro Drop oils, Avicanna expects to launch two advanced sublingual spray formulations in the upcoming weeks. The RHO Phyto product line includes oil drops, sublingual sprays, capsules and topicals with varying ratios of CBD and THC. The RHO Phyto products are designed to address a range of medical conditions that may require various rates of relief. For example, the “Rapid Act” sublingual sprays provide a faster onset of effects than the “Simple Dose” capsules and “Micro Drop” oils. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured under Good Manufacturing Practices (“GMP“) in partnership with MediPharm Labs Inc. and GMP-level analytical testing is performed by Sigma Analytical Services Inc. All RHO Phyto products will be tracked using blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.

Aras Azadian, CEO of Avicanna commented, “We believe that our RHO Phyto formulary is designed to address numerous gaps in the current medical cannabis framework with respect to patient needs and provide an opportunity to attract new prescribers and patients to medical cannabis solutions. The introduction of a strictly medical line of products, backed by extensive research, pre-clinical data, GMP manufacturing and offered by Shoppers, has the opportunity to set a new standard of care and establish RHO Phyto as the leading medical product line in the medical cannabis market.”

With the patient in mind, RHO Phyto Micro Drop oils are formulated with enhanced absorption, prolonged stability, and consistency. The blood orange flavoured Micro Drop oil 1.6 CBD – 0.06 THC and Micro Drop oil 0.6 CBD – 0.16 THC are available in a 25:1 and 4:1 CBD to THC ratio, respectively. The product name includes the amount in milligrams (mg) of CBD and THC that is delivered per dose. Detailed guidelines about dosing and titration for Health Care Practitioners (“HCPs“) and patients is available on the RHO Phyto website at www.rhophyto.com, as well as on the Avicanna Academy website at https://www.avicanna.com/the-avicanna-academy/, along with additional product information, product guidelines for patients, and frequently asked questions.

As a part of Avicanna’s commercialization strategy, the Company will be providing education and training for HCPs, patients, and medical institutions about medical cannabis and the RHO Phyto product line. Educational materials can be found on the Avicanna Academy website at https://www.avicanna.com/the-avicanna-academy/, including a recording of Avicanna’s 3rd annual symposium that was hosted virtually in partnership with Shoppers on July 21st and was live-streamed by over 1,000 participants.

The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as MyCannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care and education to their patients on the considerations and benefits that medical cannabis has to offer. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

Pura H&W: an advanced and clinically tested line of CBD consumer dermacosmetic products; and,
RHO Phyto: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its dermacosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

About My Cannabis Clinic

My Cannabis Clinic, a wholly-owned subsidiary of Avicanna, is an online health care platform that specializes in providing residents of Canada with access to cannabis and cannabinoid products for medical use. My Cannabis Clinic is devoted to providing its patients with support and education needed while using medical cannabis. My Cannabis Clinic believes in providing quality care and education to our patients about the medicinal benefits that cannabis has to offer.

Stay Connected

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to launch the RHO Phyto sublingual spray at Shoppers, the ability of the RHO Phyto products to address a range of medical conditions that may require various rates of relief, the ability of the RHO Phyto formulary to address numerous gaps in the current medical cannabis framework as well as patient needs, the ability of the Company to conduct clinical trials using various RHO Phyto products in collaboration with various leading Canadian medical institutions and the likelihood of such clinical trials evaluating the safety, tolerability and efficacy of the RHO Phyto products for treating a range conditions such as chronic pain, inflammatory bowel disorder, and their associated co-morbidities. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

Tags: cannabinoids, CSE, Marijuana, Medical Cannabis by Shoppers, Rho Phyto
Posted in Avicanna Inc., Featured | Comments Off on Avicanna’s $AVCN.ca RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical #Cannabis by #Shoppers Inc.™ $TRUL.ca $ACB

Binovi $VISN.ca Transforming K-12 Global Education Through Guided Classroom Technology Resources $EYPT $KALA

Posted by AGORACOM-JC at 4:13 PM on Tuesday, August 11th, 2020

Announced its strategic expansion into pre-K-12 Education. The expansion is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals.
Cognitive literacy skills for students of all abilities from pre-K to grade 3, with continued reading comprehension activities to grade 12, will be advanced through technology-driven vision training protocols
The company is positioned to leverage the flexibility of the Binovi Platform and empower students and teachers globally in this new post COVID-19 world

Toronto, New York – August 11, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN) | (OTC:BNVIF), a leader in neuro-vision performance technology, announces its strategic expansion into pre-K-12 Education. The expansion is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals. Cognitive literacy skills for students of all abilities from pre-K to grade 3, with continued reading comprehension activities to grade 12, will be advanced through technology-driven vision training protocols. The company is positioned to leverage the flexibility of the Binovi Platform and empower students and teachers globally in this new post COVID-19 world.

“Expanding our Binovi vision therapy technology into the field of education is the most exciting development I have seen. Research has already proven that binocular vision problems can interfere with a student’s ability to read. In fact, 80% of children diagnosed with a learning disability meet the criteria for visual accommodation and vergence problems. Knowing this, our Binovi Platform has been designed to provide early-intervention vision therapy activities to help increase reading abilities by grade three, which is the strongest predictor of high school completion and other positive life outcomes. If we can integrate our Binovi platform into the school system and have it accessible to all children as early as kindergarten, the impact of being able to detect and remediate early vision deficits, that are impeding children’s ability to read successfully by grade 3, could be a game changer,” said Terry Both, Executive Chairman, Binovi Technologies

The global education smart technology industry is growing significantly with abundant opportunities. North America plays a huge role in the development of this technology, which helps in the adoption of new learning solutions across various end-user segments. The goal of Binovi is to provide the global education sector with the best vision assessment and development tools to assist students to achieve all that they are capable. New learning opportunities are emerging as students engage with a new generation of smart technology; with smart classrooms becoming the norm, students have instant access to performance and cognitive tools that can supplement their learning success.

There is approximately 15,000 k-12 schools within Canada and over 130,000 schools within the USA. Binovi hopes to penetrate this North American education sector with our product offering and for each school we are able to license the revenue would be approximately $50k to 100k per school based upon our current pricing structure.

“Vision extends well beyond the realm of eyesight and is a fundamental component of cognition. Educators assume that each child enters the educational system with adequate visual abilities, but all too often that is not the case. Binovi technology is poised to help level the playing field among students,” commented Dr. Leonard Press, Chief Scientific Officer, Binovi Technologies

Blending personalized, online, student-driven instruction with offline, teacher-delivered lessons and activities, Binovi strives to accelerate the development of both fundamental literacy skills and higher-order thinking skills through adaptive learning paths. With a range of instructional and motivating resources, Binovi for Education will engage students in their learning success. Additionally, progress monitoring, actionable data, and scripted lessons will empower teachers to deliver literacy support specific to each students’ needs.

“The final frontiers in technology evolution is how these advancements can impact Healthcare and Education. We are now seeing these changes in real-time and look forward to becoming a global leader in the field of Education,” commented Adam Cegielski, CEO, Binovi Technologies

For additional information on the Company, please visit https://www.binovi.com/investor-reports/

About Binovi Technologies Corp.

Terry Booth

Executive Chairman

Adam Cegielski

Founder | CEO

Dr. Leonard Press OD, FAAO, FCOVD

Chief Scientific Officer

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://www.binovi.com/investor-reports/

Forward looking information:

Tags: Binovi Touch, CSE, Eli Wilson. Eye therapy, eye training, tsx
Posted in Binovi Technologies Corp. | Comments Off on Binovi $VISN.ca Transforming K-12 Global Education Through Guided Classroom Technology Resources $EYPT $KALA

Author Archive

Categories